Pliant Therapeutics Inc Total Assets
Pliant Therapeutics Inc total assets. Based on the latest financial reports, Pliant Therapeutics Inc (PLRX) holds total assets worth $189.88 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see PLRX company net worth for the company's overall valuation and market capitalisation.
Total Assets of Pliant Therapeutics Inc (2017–2025)
Total assets of Pliant Therapeutics Inc from 2017 to 2025. This chart illustrates how Pliant Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See today's stock price for Pliant Therapeutics Inc for real-time trading data and today's change.
Pliant Therapeutics Inc - Asset Composition Analysis
Pliant Therapeutics Inc Total Assets Breakdown (December 2025)
Pliant Therapeutics Inc total assets breakdown as of December 2025. Pliant Therapeutics Inc's total assets of $189.88 Million consist of 87.2% current assets and 12.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.2% |
| Accounts Receivable | $823.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Pliant Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Pliant Therapeutics Inc working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pliant Therapeutics Inc's current assets represent 87.2% of total assets in 2025, an increase from 71.8% in 2017.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2025, down from 64.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Pliant Therapeutics Inc Competitors by Total Assets
Key competitors of Pliant Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Pliant Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.90 | 12.99 | 17.69 |
| Quick Ratio | 9.90 | 12.99 | 17.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $146.66 Million | $246.85 Million | $215.66 Million |
Pliant Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Pliant Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.47 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | -43.3% |
| Total Assets | $225.23 Million |
| Market Capitalization | $53.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pliant Therapeutics Inc's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Pliant Therapeutics Inc's assets decreased by 43.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pliant Therapeutics Inc (2017–2025)
The table below shows the annual total assets of Pliant Therapeutics Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $225.23 Million | -43.26% |
| 2024-12-31 | $396.95 Million | -22.49% |
| 2023-12-31 | $512.15 Million | +46.07% |
| 2022-12-31 | $350.61 Million | +58.49% |
| 2021-12-31 | $221.22 Million | -25.15% |
| 2020-12-31 | $295.53 Million | +148.21% |
| 2019-12-31 | $119.06 Million | +78.97% |
| 2018-12-31 | $66.53 Million | +915.24% |
| 2017-12-31 | $6.55 Million | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform c… Read more